[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5Auz2OsMHEsu_2yJJYYuXBGWuB7e2ZPYe6SbFuz-IBs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":48,"rows":55},"National Eye Institute (NEI)",[4],271,false,25,48,113245,2,167,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Uveitis",36,{"name":18,"count":19},"Macular Degeneration",27,{"name":21,"count":22},"Diabetic Retinopathy",21,{"name":24,"count":25},"Cataract",20,{"name":27,"count":25},"Age-Related Macular Degeneration",{"name":29,"count":30},"Retinal Disease",14,{"name":32,"count":33},"Retinitis Pigmentosa",13,{"name":35,"count":36},"Eye Diseases",9,[38,43],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04545736","Oral Metformin for Treatment of ABCA4 Retinopathy","2028-09-30","Metformin hydrochloride",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04339764","Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration","2029-05-31","iPSC-derived RPE\u002FPLGA transplantation",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,80,104,182,246,288,329,362,384,412,439,464,489,507,525,547,572,590,615,639,665,683,701,724,746,767,785,808,885,958,1028,1089,1115,1159,1197,1231,1265,1289,1307,1330,1355,1378,1402,1428,1446,1472,1490,1513,1537,1561,1579,1600,1626,1644,1662,1685,1710,1732,1754,1777,1800,1824,1848,1871,1894,1912,1936,1959,1982,2006,2029,2050,2072,2094,2128,2158],{"intervention":47,"totalTrials":57,"cells":58},1,{"EARLY_PHASE1":59,"PHASE1":62,"PHASE2":64,"PHASE3":74,"PHASE4":76,"NA":78},{"trials":60,"activeCount":61},[],0,{"trials":63,"activeCount":61},[],{"trials":65,"activeCount":57,"soonestReadout":46},[66],{"nctId":44,"briefTitle":45,"status":67,"phases":68,"primaryCompletion":46,"completion":46,"start":69,"enrollment":25,"conditions":70,"interventions":73},"RECRUITING",[50,51],"2020-09-23",[71,72],"Dry Age-Related Macular Degeneration","Geographic Atrophy",[47],{"trials":75,"activeCount":61},[],{"trials":77,"activeCount":61},[],{"trials":79,"activeCount":61},[],{"intervention":42,"totalTrials":57,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":98,"PHASE4":100,"NA":102},{"trials":83,"activeCount":61},[],{"trials":85,"activeCount":61},[],{"trials":87,"activeCount":57,"soonestReadout":41},[88],{"nctId":39,"briefTitle":40,"status":67,"phases":89,"primaryCompletion":41,"completion":41,"start":90,"enrollment":91,"conditions":92,"interventions":97},[50,51],"2020-11-23",56,[93,94,95,96],"ABCA4 Retinopathy","Stargardt Disease","Retinal Dystrophy","Retinal Degeneration",[42],{"trials":99,"activeCount":61},[],{"trials":101,"activeCount":61},[],{"trials":103,"activeCount":61},[],{"intervention":105,"totalTrials":106,"cells":107},"Triamcinolone Acetonide",6,{"EARLY_PHASE1":108,"PHASE1":121,"PHASE2":142,"PHASE3":144,"PHASE4":178,"NA":180},{"trials":109,"activeCount":61},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT00411333","Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy","COMPLETED",[49],"2009-07","2006-07",100,[21],[120],"triamcinolone acetonide",{"trials":122,"activeCount":61},[123,133],{"nctId":124,"briefTitle":125,"status":113,"phases":126,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT00071227","Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders",[50],"2007-08-15","2003-10-15",16,[18,131],"Retinal Vein Occlusion",[105],{"nctId":134,"briefTitle":135,"status":113,"phases":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":141},"NCT00101764","Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders",[50],"2008-05-20","2005-01-05",120,[18,131,21],[105],{"trials":143,"activeCount":61},[],{"trials":145,"activeCount":61},[146,157,168],{"nctId":147,"briefTitle":148,"status":113,"phases":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":156},"NCT00105404","Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation",[52],"2006-10-30","2005-03-09",5,[21,154,155],"Diabetic Macular Edema","DME",[105],{"nctId":158,"briefTitle":159,"status":113,"phases":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":167},"NCT00106132","Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage",[52],"2005-11","2005-03",1260,[131,165,166],"Macular Edema, Cystoid","Macular Edema",[105],{"nctId":169,"briefTitle":170,"status":113,"phases":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT00100009","Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration",[52],"2006-12-20","2004-12-09",30,[18],[177,105],"TAC-PF",{"trials":179,"activeCount":61},[],{"trials":181,"activeCount":61},[],{"intervention":183,"totalTrials":152,"cells":184},"Vitamin E",{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":218,"PHASE3":220,"PHASE4":242,"NA":244},{"trials":186,"activeCount":61},[],{"trials":188,"activeCount":61},[189,199,209],{"nctId":190,"briefTitle":191,"status":113,"phases":192,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT00021645","Vitamin E to Treat Uveitis-Associated Macular Edema",[50],"2004-06","2001-07",80,[197,15],"Cystoid Macular Edema",[183],{"nctId":200,"briefTitle":201,"status":113,"phases":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT00027287","Laser and Medical Treatment of Diabetic Macular Edema",[50],"2002-12","2001-11",60,[207,166],"Diabetes Mellitus",[183],{"nctId":210,"briefTitle":211,"status":113,"phases":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"NCT00055042","Laser and Antioxidant Treatment of Diabetic Macular Edema",[50],"2004-01","2003-02",40,[166,207],[183],{"trials":219,"activeCount":61},[],{"trials":221,"activeCount":61},[222,233],{"nctId":223,"briefTitle":224,"status":225,"phases":226,"start":227,"conditions":228,"interventions":229},"NCT00000161","Randomized Trials of Vitamin Supplements and Eye Disease","UNKNOWN",[52],"1993-08",[18,24],[230,231,232,183],"Aspirin","Beta-Carotene","Vitamin C",{"nctId":234,"briefTitle":235,"status":113,"phases":236,"completion":237,"start":238,"conditions":239,"interventions":240},"NCT00000114","Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa",[52],"1987-06","1984-05",[32],[183,241],"Vitamin A",{"trials":243,"activeCount":61},[],{"trials":245,"activeCount":61},[],{"intervention":230,"totalTrials":247,"cells":248},4,{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":284,"NA":286},{"trials":250,"activeCount":61},[],{"trials":252,"activeCount":61},[],{"trials":254,"activeCount":61},[],{"trials":256,"activeCount":61},[257,266,270,276],{"nctId":258,"briefTitle":259,"status":260,"phases":261,"completion":262,"start":263,"conditions":264,"interventions":265},"NCT00000157","Randomized Trial of Aspirin and Cataracts in U.S. Physicians","TERMINATED",[52],"1988-01","1982-04",[24],[230],{"nctId":223,"briefTitle":224,"status":225,"phases":267,"start":227,"conditions":268,"interventions":269},[52],[18,24],[230,231,232,183],{"nctId":271,"briefTitle":272,"status":225,"phases":273,"start":263,"conditions":274,"interventions":275},"NCT00000152","Randomized Trial of Beta-Carotene and Macular Degeneration",[52],[18],[230,231],{"nctId":277,"briefTitle":278,"status":113,"phases":279,"start":280,"conditions":281,"interventions":283},"NCT00000151","Early Treatment Diabetic Retinopathy Study (ETDRS)",[52],"1979-12",[282,21],"Blindness",[230],{"trials":285,"activeCount":61},[],{"trials":287,"activeCount":61},[],{"intervention":289,"totalTrials":290,"cells":291},"Lutein",3,{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":303,"PHASE3":314,"PHASE4":325,"NA":327},{"trials":293,"activeCount":61},[],{"trials":295,"activeCount":61},[296],{"nctId":297,"briefTitle":298,"status":113,"phases":299,"completion":127,"start":300,"enrollment":215,"conditions":301,"interventions":302},"NCT00121589","Lutein\u002FZeaxanthin and Omega-3 Supplementation in Persons Over Age 60",[50],"2005-07-14",[18],[289],{"trials":304,"activeCount":61},[305],{"nctId":306,"briefTitle":307,"status":113,"phases":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT00006202","Lutein for Age-Related Macular Degeneration",[51],"2003-08","2000-09",45,[18],[289],{"trials":315,"activeCount":61},[316],{"nctId":317,"briefTitle":318,"status":113,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":324},"NCT00346333","Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A",[52],"2008-12","2003-07",240,[32],[289],{"trials":326,"activeCount":61},[],{"trials":328,"activeCount":61},[],{"intervention":330,"totalTrials":11,"cells":331},"Acyclovir",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":358,"NA":360},{"trials":333,"activeCount":61},[],{"trials":335,"activeCount":61},[],{"trials":337,"activeCount":61},[],{"trials":339,"activeCount":61},[340,350],{"nctId":341,"briefTitle":342,"status":113,"phases":343,"start":344,"conditions":345,"interventions":349},"NCT00000139","Herpetic Eye Disease Study (HEDS) II",[52],"1992-10",[346,347,348],"Keratitis, Herpetic","Ocular Herpes Simplex","Herpes Simplex",[330],{"nctId":351,"briefTitle":352,"status":225,"phases":353,"start":354,"conditions":355,"interventions":356},"NCT00000138","Herpetic Eye Disease Study (HEDS) I",[52],"1989-05",[346,347],[357,330],"Prednisolone Phosphate",{"trials":359,"activeCount":61},[],{"trials":361,"activeCount":61},[],{"intervention":231,"totalTrials":11,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":380,"NA":382},{"trials":365,"activeCount":61},[],{"trials":367,"activeCount":61},[],{"trials":369,"activeCount":61},[],{"trials":371,"activeCount":61},[372,376],{"nctId":223,"briefTitle":224,"status":225,"phases":373,"start":227,"conditions":374,"interventions":375},[52],[18,24],[230,231,232,183],{"nctId":271,"briefTitle":272,"status":225,"phases":377,"start":263,"conditions":378,"interventions":379},[52],[18],[230,231],{"trials":381,"activeCount":61},[],{"trials":383,"activeCount":61},[],{"intervention":385,"totalTrials":11,"cells":386},"Celecoxib",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":401,"PHASE4":408,"NA":410},{"trials":388,"activeCount":61},[],{"trials":390,"activeCount":61},[],{"trials":392,"activeCount":61},[393],{"nctId":394,"briefTitle":395,"status":113,"phases":396,"completion":397,"start":398,"enrollment":205,"conditions":399,"interventions":400},"NCT00043680","Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy",[51],"2005-01","2002-08",[18],[385],{"trials":402,"activeCount":61},[403],{"nctId":404,"briefTitle":201,"status":113,"phases":405,"completion":116,"start":203,"enrollment":117,"conditions":406,"interventions":407},"NCT00050479",[52],[18],[385],{"trials":409,"activeCount":61},[],{"trials":411,"activeCount":61},[],{"intervention":241,"totalTrials":11,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":427,"PHASE3":429,"PHASE4":435,"NA":437},{"trials":415,"activeCount":61},[],{"trials":417,"activeCount":61},[418],{"nctId":419,"briefTitle":420,"status":113,"phases":421,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":426},"NCT00065455","Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa",[50],"2009-05-06","2003-07-17",11,[32],[241],{"trials":428,"activeCount":61},[],{"trials":430,"activeCount":61},[431],{"nctId":234,"briefTitle":235,"status":113,"phases":432,"completion":237,"start":238,"conditions":433,"interventions":434},[52],[32],[183,241],{"trials":436,"activeCount":61},[],{"trials":438,"activeCount":61},[],{"intervention":440,"totalTrials":57,"cells":441},"Lutein\u002Fzeaxanthin and DHA\u002FEPA",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":460,"NA":462},{"trials":443,"activeCount":61},[],{"trials":445,"activeCount":61},[],{"trials":447,"activeCount":61},[],{"trials":449,"activeCount":61},[450],{"nctId":451,"briefTitle":452,"status":113,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT00345176","Age-Related Eye Disease Study 2 (AREDS2)",[52],"2012-10","2006-09",4203,[458,24],"Age-related Macular Degeneration",[440],{"trials":461,"activeCount":61},[],{"trials":463,"activeCount":61},[],{"intervention":465,"totalTrials":57,"cells":466},"Erythromycin Ointment",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":485,"NA":487},{"trials":468,"activeCount":61},[],{"trials":470,"activeCount":61},[],{"trials":472,"activeCount":61},[],{"trials":474,"activeCount":61},[475],{"nctId":476,"briefTitle":477,"status":113,"phases":478,"start":479,"conditions":480,"interventions":483},"NCT00000120","Clinical Trial of Eye Prophylaxis in the Newborn",[52],"1985-01",[481,482],"Chlamydia Infections","Ophthalmia Neonatorum",[465,484],"Silver Nitrate Drops",{"trials":486,"activeCount":61},[],{"trials":488,"activeCount":61},[],{"intervention":484,"totalTrials":57,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":503,"NA":505},{"trials":492,"activeCount":61},[],{"trials":494,"activeCount":61},[],{"trials":496,"activeCount":61},[],{"trials":498,"activeCount":61},[499],{"nctId":476,"briefTitle":477,"status":113,"phases":500,"start":479,"conditions":501,"interventions":502},[52],[481,482],[465,484],{"trials":504,"activeCount":61},[],{"trials":506,"activeCount":61},[],{"intervention":232,"totalTrials":57,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":521,"NA":523},{"trials":510,"activeCount":61},[],{"trials":512,"activeCount":61},[],{"trials":514,"activeCount":61},[],{"trials":516,"activeCount":61},[517],{"nctId":223,"briefTitle":224,"status":225,"phases":518,"start":227,"conditions":519,"interventions":520},[52],[18,24],[230,231,232,183],{"trials":522,"activeCount":61},[],{"trials":524,"activeCount":61},[],{"intervention":526,"totalTrials":57,"cells":527},"Sorbinil",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":543,"NA":545},{"trials":529,"activeCount":61},[],{"trials":531,"activeCount":61},[],{"trials":533,"activeCount":61},[],{"trials":535,"activeCount":61},[536],{"nctId":537,"briefTitle":538,"status":113,"phases":539,"start":540,"conditions":541,"interventions":542},"NCT00000159","Sorbinil Retinopathy Trial (SRT)",[52],"1983-08",[21,207],[526],{"trials":544,"activeCount":61},[],{"trials":546,"activeCount":61},[],{"intervention":548,"totalTrials":57,"cells":549},"Intravitreal Antibiotics",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":568,"NA":570},{"trials":551,"activeCount":61},[],{"trials":553,"activeCount":61},[],{"trials":555,"activeCount":61},[],{"trials":557,"activeCount":61},[558],{"nctId":559,"briefTitle":560,"status":113,"phases":561,"completion":562,"start":563,"conditions":564,"interventions":567},"NCT00000130","Endophthalmitis Vitrectomy Study (EVS)",[52],"1995-01","1990-02",[565,566],"Endophthalmitis","Eye Infections",[548],{"trials":569,"activeCount":61},[],{"trials":571,"activeCount":61},[],{"intervention":357,"totalTrials":57,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":586,"NA":588},{"trials":575,"activeCount":61},[],{"trials":577,"activeCount":61},[],{"trials":579,"activeCount":61},[],{"trials":581,"activeCount":61},[582],{"nctId":351,"briefTitle":352,"status":225,"phases":583,"start":354,"conditions":584,"interventions":585},[52],[346,347],[357,330],{"trials":587,"activeCount":61},[],{"trials":589,"activeCount":61},[],{"intervention":591,"totalTrials":57,"cells":592},"Atropine",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":611,"NA":613},{"trials":594,"activeCount":61},[],{"trials":596,"activeCount":61},[],{"trials":598,"activeCount":61},[],{"trials":600,"activeCount":61},[601],{"nctId":602,"briefTitle":603,"status":113,"phases":604,"completion":204,"start":605,"enrollment":25,"conditions":606,"interventions":610},"NCT00001864","Amblyopia (Lazy Eye) Treatment Study",[52],"1999-05",[607,608,609],"Amblyopia","Anisometropia","Strabismus",[591],{"trials":612,"activeCount":61},[],{"trials":614,"activeCount":61},[],{"intervention":616,"totalTrials":57,"cells":617},"Immunoglobulin",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":635,"NA":637},{"trials":619,"activeCount":61},[],{"trials":621,"activeCount":61},[],{"trials":623,"activeCount":61},[],{"trials":625,"activeCount":61},[626],{"nctId":627,"briefTitle":628,"status":113,"phases":629,"completion":630,"start":631,"conditions":632,"interventions":634},"NCT00000117","Intravenous Immunoglobulin Therapy in Optic Neuritis",[52],"1997-12","1995-08",[633],"Optic Neuritis",[616],{"trials":636,"activeCount":61},[],{"trials":638,"activeCount":61},[],{"intervention":640,"totalTrials":57,"cells":641},"Perfluoropropane",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":661,"NA":663},{"trials":643,"activeCount":61},[],{"trials":645,"activeCount":61},[],{"trials":647,"activeCount":61},[],{"trials":649,"activeCount":61},[650],{"nctId":651,"briefTitle":652,"status":113,"phases":653,"start":654,"conditions":655,"interventions":658},"NCT00000140","The Silicone Study",[52],"1985-09",[656,657],"Proliferative Vitreoretinopathy","Retinal Detachment",[640,659,660],"Sulfur Hexafluoride","Silicone Oil",{"trials":662,"activeCount":61},[],{"trials":664,"activeCount":61},[],{"intervention":659,"totalTrials":57,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":679,"NA":681},{"trials":668,"activeCount":61},[],{"trials":670,"activeCount":61},[],{"trials":672,"activeCount":61},[],{"trials":674,"activeCount":61},[675],{"nctId":651,"briefTitle":652,"status":113,"phases":676,"start":654,"conditions":677,"interventions":678},[52],[656,657],[640,659,660],{"trials":680,"activeCount":61},[],{"trials":682,"activeCount":61},[],{"intervention":660,"totalTrials":57,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":697,"NA":699},{"trials":686,"activeCount":61},[],{"trials":688,"activeCount":61},[],{"trials":690,"activeCount":61},[],{"trials":692,"activeCount":61},[693],{"nctId":651,"briefTitle":652,"status":113,"phases":694,"start":654,"conditions":695,"interventions":696},[52],[656,657],[640,659,660],{"trials":698,"activeCount":61},[],{"trials":700,"activeCount":61},[],{"intervention":702,"totalTrials":57,"cells":703},"Beta Blocker",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":720,"NA":722},{"trials":705,"activeCount":61},[],{"trials":707,"activeCount":61},[],{"trials":709,"activeCount":61},[],{"trials":711,"activeCount":61},[712],{"nctId":713,"briefTitle":714,"status":225,"phases":715,"start":716,"conditions":717,"interventions":719},"NCT00000149","Collaborative Initial Glaucoma Treatment Study (CIGTS)",[52],"1993-10",[718],"Open-Angle Glaucoma",[702],{"trials":721,"activeCount":61},[],{"trials":723,"activeCount":61},[],{"intervention":725,"totalTrials":57,"cells":726},"TNFR:Fc",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":742,"NA":744},{"trials":728,"activeCount":61},[],{"trials":730,"activeCount":61},[],{"trials":732,"activeCount":61},[],{"trials":734,"activeCount":61},[735],{"nctId":736,"briefTitle":737,"status":225,"phases":738,"conditions":739,"interventions":741},"NCT00012506","The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis",[52],[15,740],"Arthritis, Juvenile Rheumatoid",[725],{"trials":743,"activeCount":61},[],{"trials":745,"activeCount":61},[],{"intervention":747,"totalTrials":57,"cells":748},"Betaxolol",{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":755,"PHASE4":763,"NA":765},{"trials":750,"activeCount":61},[],{"trials":752,"activeCount":61},[],{"trials":754,"activeCount":61},[],{"trials":756,"activeCount":61},[757],{"nctId":758,"briefTitle":759,"status":225,"phases":760,"start":344,"conditions":761,"interventions":762},"NCT00000132","Early Manifest Glaucoma Trial (EMGT)",[52],[718],[747],{"trials":764,"activeCount":61},[],{"trials":766,"activeCount":61},[],{"intervention":177,"totalTrials":57,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":781,"NA":783},{"trials":770,"activeCount":61},[],{"trials":772,"activeCount":61},[],{"trials":774,"activeCount":61},[],{"trials":776,"activeCount":61},[777],{"nctId":169,"briefTitle":170,"status":113,"phases":778,"completion":172,"start":173,"enrollment":174,"conditions":779,"interventions":780},[52],[18],[177,105],{"trials":782,"activeCount":61},[],{"trials":784,"activeCount":61},[],{"intervention":786,"totalTrials":57,"cells":787},"5-Fluorouracil",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":804,"NA":806},{"trials":789,"activeCount":61},[],{"trials":791,"activeCount":61},[],{"trials":793,"activeCount":61},[],{"trials":795,"activeCount":61},[796],{"nctId":797,"briefTitle":798,"status":113,"phases":799,"completion":800,"start":654,"conditions":801,"interventions":803},"NCT00000122","Fluorouracil Filtering Surgery Study (FFSS)",[52],"1988-06",[802],"Glaucoma",[786],{"trials":805,"activeCount":61},[],{"trials":807,"activeCount":61},[],{"intervention":809,"totalTrials":810,"cells":811},"Daclizumab",7,{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":833,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":813,"activeCount":61},[],{"trials":815,"activeCount":61},[816,825],{"nctId":817,"briefTitle":818,"status":113,"phases":819,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":824},"NCT00001526","ANTI-TAC THERAPY FOR UVEITIS",[50],"2007-09-06","1996-06-04",15,[15],[809],{"nctId":826,"briefTitle":827,"status":113,"phases":828,"completion":829,"start":830,"enrollment":106,"conditions":831,"interventions":832},"NCT00078689","Daclizumab and Sirolimus to Treat Uveitis",[50],"2008-07-18","2004-03-03",[15],[809],{"trials":834,"activeCount":61},[835,842,851,863,871],{"nctId":836,"briefTitle":837,"status":113,"phases":838,"completion":839,"start":398,"enrollment":822,"conditions":840,"interventions":841},"NCT00043667","Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis",[51],"2004-10",[15],[809],{"nctId":843,"briefTitle":844,"status":113,"phases":845,"completion":193,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT00001865","HAT in Eye Complications of Behcet's Disease",[51],"1999-07",26,[849,29,15],"Behcet's Syndrome",[809],{"nctId":852,"briefTitle":853,"status":113,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":106,"conditions":857,"interventions":862},"NCT00130637","Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis",[51],"2008-05","2005-08",[858,859,860,861],"Anterior Uveitis","Arthritis, Juvenile Idiopathic","Iritis","Immunosuppression",[809],{"nctId":864,"briefTitle":865,"status":113,"phases":866,"completion":172,"start":867,"enrollment":152,"conditions":868,"interventions":870},"NCT00326508","Combination Daclizumab\u002FDenileukin Diftitox to Treat Uveitis",[51],"2006-05-11",[869],"Non-infectious Intermediate and Posterior Uveitis",[809],{"nctId":872,"briefTitle":873,"status":113,"phases":874,"completion":875,"start":876,"enrollment":106,"conditions":877,"interventions":878},"NCT00070759","Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis",[51],"2006-10-02","2003-10-06",[15],[809],{"trials":880,"activeCount":61},[],{"trials":882,"activeCount":61},[],{"trials":884,"activeCount":61},[],{"intervention":886,"totalTrials":810,"cells":887},"Ranibizumab",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":932,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":889,"activeCount":61},[],{"trials":891,"activeCount":61},[892,901,910,916,924],{"nctId":893,"briefTitle":894,"status":113,"phases":895,"completion":896,"start":897,"enrollment":152,"conditions":898,"interventions":900},"NCT00457145","Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation",[50],"2007-10-24","2007-03-27",[899],"Telangiectasia",[886],{"nctId":902,"briefTitle":903,"status":113,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":152,"conditions":907,"interventions":909},"NCT00685854","Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth",[50],"2011-03-24","2008-05-21",[908],"Macular Telangiectasia",[886],{"nctId":911,"briefTitle":912,"status":113,"phases":913,"completion":896,"start":897,"enrollment":152,"conditions":914,"interventions":915},"NCT00457067","Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation",[50],[899],[886],{"nctId":917,"briefTitle":918,"status":113,"phases":919,"primaryCompletion":920,"completion":920,"start":906,"enrollment":57,"conditions":921,"interventions":923},"NCT00685503","Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth",[50],"2011-04-12",[922],"Neovascularization",[886],{"nctId":925,"briefTitle":926,"status":113,"phases":927,"completion":127,"start":928,"enrollment":152,"conditions":929,"interventions":931},"NCT00089765","Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome",[50],"2004-08-10",[930],"Von Hippel-Lindau Syndrome",[886],{"trials":933,"activeCount":61},[934,943],{"nctId":935,"briefTitle":936,"status":113,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":91,"conditions":940,"interventions":941},"NCT01610557","Ranibizumab and Bevacizumab for Diabetic Macular Edema",[51],"2015-02","2012-05",[154],[886,942],"Bevacizumab",{"nctId":944,"briefTitle":945,"status":113,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":290,"conditions":949,"interventions":950},"NCT02859441","A Phase I\u002FII Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab",[50,51],"2019-07-09","2017-01-23",[930],[886,951],"E10030",{"trials":953,"activeCount":61},[],{"trials":955,"activeCount":61},[],{"trials":957,"activeCount":61},[],{"intervention":959,"totalTrials":106,"cells":960},"Sirolimus",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":973,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":962,"activeCount":61},[],{"trials":964,"activeCount":61},[965],{"nctId":966,"briefTitle":967,"status":113,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":152,"conditions":971,"interventions":972},"NCT00876434","Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti",[50],"2011-02-10","2009-04-01",[858],[959],{"trials":974,"activeCount":61},[975,983,994,1004,1013],{"nctId":976,"briefTitle":977,"status":113,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":152,"conditions":981,"interventions":982},"NCT00711490","Sirolimus to Treat Diabetic Macular Edema",[50,51],"2011-01","2008-07",[21],[959],{"nctId":984,"briefTitle":985,"status":260,"phases":986,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT01675947","Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy",[51],"2015-06","2016-02","2012-02",52,[72],[959,993],"Lidocaine",{"nctId":995,"briefTitle":996,"status":113,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":152,"conditions":1001,"interventions":1003},"NCT01517074","Sirolimus Injections for Autoimmune Scleritis",[50,51],"2013-05","2014-04","2012-01",[1002],"Scleritis",[959],{"nctId":1005,"briefTitle":1006,"status":113,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":424,"conditions":1011,"interventions":1012},"NCT00766649","Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD",[50,51],"2012-04","2012-07","2008-10",[27],[959],{"nctId":1014,"briefTitle":1015,"status":113,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":106,"conditions":1020,"interventions":1021},"NCT01445548","Sirolimus for Advanced Age-Related Macular Degeneration",[50,51],"2013-04","2014-02","2011-09",[27,72],[959],{"trials":1023,"activeCount":61},[],{"trials":1025,"activeCount":61},[],{"trials":1027,"activeCount":61},[],{"intervention":1029,"totalTrials":152,"cells":1030},"Minocycline",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1032,"activeCount":61},[],{"trials":1034,"activeCount":61},[],{"trials":1036,"activeCount":61},[1037,1046,1055,1065,1074],{"nctId":1038,"briefTitle":1039,"status":113,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":36,"conditions":1044,"interventions":1045},"NCT01468831","Minocycline to Treat Branch Retinal Vein Occlusion",[50,51],"2020-02-25","2021-03-18","2012-03-28",[131],[1029,942],{"nctId":1047,"briefTitle":1048,"status":113,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":106,"conditions":1053,"interventions":1054},"NCT01468844","Minocycline to Treat Central Retinal Vein Occlusion",[50,51],"2015-03-04","2015-05-13","2011-12-21",[131],[1029,942],{"nctId":1056,"briefTitle":1057,"status":113,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1064},"NCT02564978","Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration",[51],"2022-09-28","2023-03-08","2016-12-14",37,[27],[1029],{"nctId":1066,"briefTitle":1067,"status":113,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":106,"conditions":1072,"interventions":1073},"NCT01120899","A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema",[50,51],"2011-08","2013-02","2010-04",[154],[1029],{"nctId":1075,"briefTitle":1076,"status":113,"phases":1077,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":810,"conditions":1081,"interventions":1082},"NCT02140164","Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa",[50,51],"2015-11","2016-06","2014-05",[32],[1029],{"trials":1084,"activeCount":61},[],{"trials":1086,"activeCount":61},[],{"trials":1088,"activeCount":61},[],{"intervention":942,"totalTrials":290,"cells":1090},{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1092,"activeCount":61},[],{"trials":1094,"activeCount":61},[],{"trials":1096,"activeCount":61},[1097,1101,1105],{"nctId":1038,"briefTitle":1039,"status":113,"phases":1098,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":36,"conditions":1099,"interventions":1100},[50,51],[131],[1029,942],{"nctId":1047,"briefTitle":1048,"status":113,"phases":1102,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":106,"conditions":1103,"interventions":1104},[50,51],[131],[1029,942],{"nctId":935,"briefTitle":936,"status":113,"phases":1106,"primaryCompletion":938,"completion":938,"start":939,"enrollment":91,"conditions":1107,"interventions":1108},[51],[154],[886,942],{"trials":1110,"activeCount":61},[],{"trials":1112,"activeCount":61},[],{"trials":1114,"activeCount":61},[],{"intervention":1116,"totalTrials":290,"cells":1117},"Interferon gamma-1b",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1119,"activeCount":61},[],{"trials":1121,"activeCount":61},[],{"trials":1123,"activeCount":61},[1124,1135,1144],{"nctId":1125,"briefTitle":1126,"status":260,"phases":1127,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":247,"conditions":1131,"interventions":1134},"NCT02338973","Interferon Gamma-1b Administered Topically for Macular Edema\u002FIntraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)",[50,51],"2018-06-01","2018-07-26","2015-01-14",[1132,1133],"Inherited Ophthalmic Diseases","Inherited Retinal Degeneration",[1116],{"nctId":1136,"briefTitle":1137,"status":113,"phases":1138,"primaryCompletion":1139,"completion":1018,"start":1140,"enrollment":152,"conditions":1141,"interventions":1143},"NCT01468337","Topical Interferon Gamma-1b for Central Serous Chorioretinopathy",[50,51],"2013-11","2011-10",[29,1142],"Macular Disease",[1116],{"nctId":1145,"briefTitle":1146,"status":113,"phases":1147,"primaryCompletion":989,"completion":1148,"start":1149,"enrollment":152,"conditions":1150,"interventions":1151},"NCT01376362","Topical Interferon Gamma for Macular Edema Secondary to Uveitis",[50,51],"2012-03","2011-06",[858,15],[1152],"Interferon Gamma-1b",{"trials":1154,"activeCount":61},[],{"trials":1156,"activeCount":61},[],{"trials":1158,"activeCount":61},[],{"intervention":1160,"totalTrials":290,"cells":1161},"Finasteride",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1163,"activeCount":61},[],{"trials":1165,"activeCount":61},[],{"trials":1167,"activeCount":61},[1168,1177,1184],{"nctId":1169,"briefTitle":1170,"status":113,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":290,"conditions":1175,"interventions":1176},"NCT01227993","Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy",[50,51],"2012-12","2013-06","2010-10",[29],[1160],{"nctId":1178,"briefTitle":1179,"status":260,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1008,"enrollment":106,"conditions":1182,"interventions":1183},"NCT01585441","Finasteride for Chronic Central Serous Chorioretinopathy",[51],"2013-12",[29],[1160],{"nctId":1185,"briefTitle":1186,"status":113,"phases":1187,"primaryCompletion":1071,"completion":1071,"start":1188,"enrollment":152,"conditions":1189,"interventions":1190},"NCT00837252","Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy",[50,51],"2009-02",[29],[1160],{"trials":1192,"activeCount":61},[],{"trials":1194,"activeCount":61},[],{"trials":1196,"activeCount":61},[],{"intervention":1198,"totalTrials":11,"cells":1199},"Cysteamine",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1214,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1201,"activeCount":61},[],{"trials":1203,"activeCount":61},[1204],{"nctId":1205,"briefTitle":1206,"status":113,"phases":1207,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1213},"NCT00001736","New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis",[50],"2001-03","1998-05",51,[1212],"Cystinosis",[1198],{"trials":1215,"activeCount":61},[1216],{"nctId":1217,"briefTitle":1218,"status":113,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1224},"NCT00001213","Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis",[51],"2013-07","1986-04",328,[1212],[1198],{"trials":1226,"activeCount":61},[],{"trials":1228,"activeCount":61},[],{"trials":1230,"activeCount":61},[],{"intervention":1232,"totalTrials":11,"cells":1233},"Ustekinumab",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1259,"PHASE4":1261,"NA":1263},{"trials":1235,"activeCount":61},[],{"trials":1237,"activeCount":61},[],{"trials":1239,"activeCount":61},[1240,1250],{"nctId":1241,"briefTitle":1242,"status":113,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT02911116","Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)",[51],"2020-03-05","2020-05-28","2017-03-30",8,[15],[1232,1232],{"nctId":1251,"briefTitle":1252,"status":1253,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":61,"conditions":1257,"interventions":1258},"NCT01647152","Ustekinumab for Active Sight-Threatening Uveitis","WITHDRAWN",[50,51],"2015-06-30","2012-07-03",[15],[1232],{"trials":1260,"activeCount":61},[],{"trials":1262,"activeCount":61},[],{"trials":1264,"activeCount":61},[],{"intervention":1266,"totalTrials":57,"cells":1267},"Enbrel",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1269,"activeCount":61},[],{"trials":1271,"activeCount":61},[],{"trials":1273,"activeCount":61},[1274],{"nctId":1275,"briefTitle":1276,"status":113,"phases":1277,"completion":1278,"start":1279,"enrollment":822,"conditions":1280,"interventions":1282},"NCT00001862","TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis",[51],"2003-03","1999-02",[1281,15],"Juvenile Rheumatoid Arthritis",[1266],{"trials":1284,"activeCount":61},[],{"trials":1286,"activeCount":61},[],{"trials":1288,"activeCount":61},[],{"intervention":993,"totalTrials":57,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":61},[],{"trials":1294,"activeCount":61},[],{"trials":1296,"activeCount":61},[1297],{"nctId":984,"briefTitle":985,"status":260,"phases":1298,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":1299,"interventions":1300},[51],[72],[959,993],{"trials":1302,"activeCount":61},[],{"trials":1304,"activeCount":61},[],{"trials":1306,"activeCount":61},[],{"intervention":1308,"totalTrials":57,"cells":1309},"Methotrexate",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1311,"activeCount":61},[],{"trials":1313,"activeCount":61},[],{"trials":1315,"activeCount":61},[1316],{"nctId":1317,"briefTitle":1318,"status":260,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":11,"conditions":1322,"interventions":1323},"NCT01314417","Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate",[50,51],"2013-01","2011-02",[869],[1308],{"trials":1325,"activeCount":61},[],{"trials":1327,"activeCount":61},[],{"trials":1329,"activeCount":61},[],{"intervention":1331,"totalTrials":57,"cells":1332},"NT-501 CNTF-releasing implant",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1334,"activeCount":61},[],{"trials":1336,"activeCount":61},[],{"trials":1338,"activeCount":61},[1339],{"nctId":1340,"briefTitle":1341,"status":113,"phases":1342,"primaryCompletion":1343,"completion":1344,"start":1009,"enrollment":152,"conditions":1345,"interventions":1348},"NCT01648452","CNTF Implants for CNGB3 Achromatopsia",[50,51],"2013-03","2015-10",[1346,1347],"Eye Disease","Achromatopsia",[1331],{"trials":1350,"activeCount":61},[],{"trials":1352,"activeCount":61},[],{"trials":1354,"activeCount":61},[],{"intervention":1356,"totalTrials":57,"cells":1357},"B27PD",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1359,"activeCount":61},[],{"trials":1361,"activeCount":61},[],{"trials":1363,"activeCount":61},[1364],{"nctId":1365,"briefTitle":1366,"status":113,"phases":1367,"primaryCompletion":1139,"completion":1018,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1371},"NCT01195948","Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis",[50,51],"2010-08",31,[15],[1356],{"trials":1373,"activeCount":61},[],{"trials":1375,"activeCount":61},[],{"trials":1377,"activeCount":61},[],{"intervention":1379,"totalTrials":57,"cells":1380},"Peribulbar Triamcinolone Acetonide",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1382,"activeCount":61},[],{"trials":1384,"activeCount":61},[],{"trials":1386,"activeCount":61},[1387],{"nctId":1388,"briefTitle":1389,"status":113,"phases":1390,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1395},"NCT00231023","Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema",[51],"2006-05","2005-09",10,[21],[1379],{"trials":1397,"activeCount":61},[],{"trials":1399,"activeCount":61},[],{"trials":1401,"activeCount":61},[],{"intervention":1403,"totalTrials":57,"cells":1404},"Nitisinone",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1422,"PHASE4":1424,"NA":1426},{"trials":1406,"activeCount":61},[],{"trials":1408,"activeCount":61},[],{"trials":1410,"activeCount":61},[1411],{"nctId":1412,"briefTitle":1413,"status":113,"phases":1414,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":152,"conditions":1418,"interventions":1421},"NCT01838655","Nitisinone for Type 1B Oculocutaneous Albinism",[50,51],"2016-07-11","2017-02-07","2013-04-16",[1419,1420],"Albinism","Vision Loss",[1403],{"trials":1423,"activeCount":61},[],{"trials":1425,"activeCount":61},[],{"trials":1427,"activeCount":61},[],{"intervention":951,"totalTrials":57,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1431,"activeCount":61},[],{"trials":1433,"activeCount":61},[],{"trials":1435,"activeCount":61},[1436],{"nctId":944,"briefTitle":945,"status":113,"phases":1437,"primaryCompletion":947,"completion":947,"start":948,"enrollment":290,"conditions":1438,"interventions":1439},[50,51],[930],[886,951],{"trials":1441,"activeCount":61},[],{"trials":1443,"activeCount":61},[],{"trials":1445,"activeCount":61},[],{"intervention":1447,"totalTrials":57,"cells":1448},"ASEDs",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1466,"PHASE4":1468,"NA":1470},{"trials":1450,"activeCount":61},[],{"trials":1452,"activeCount":61},[],{"trials":1454,"activeCount":61},[1455],{"nctId":1456,"briefTitle":1457,"status":260,"phases":1458,"primaryCompletion":1459,"completion":1460,"start":1139,"enrollment":1461,"conditions":1462,"interventions":1464},"NCT01972438","A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients",[51],"2015-05","2016-01",18,[1463],"Graft vs Host Disease",[1447,1465],"Saline",{"trials":1467,"activeCount":61},[],{"trials":1469,"activeCount":61},[],{"trials":1471,"activeCount":61},[],{"intervention":1465,"totalTrials":57,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1484,"PHASE4":1486,"NA":1488},{"trials":1475,"activeCount":61},[],{"trials":1477,"activeCount":61},[],{"trials":1479,"activeCount":61},[1480],{"nctId":1456,"briefTitle":1457,"status":260,"phases":1481,"primaryCompletion":1459,"completion":1460,"start":1139,"enrollment":1461,"conditions":1482,"interventions":1483},[51],[1463],[1447,1465],{"trials":1485,"activeCount":61},[],{"trials":1487,"activeCount":61},[],{"trials":1489,"activeCount":61},[],{"intervention":1491,"totalTrials":57,"cells":1492},"Dextromethorphan hydrobromide",{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1494,"activeCount":61},[],{"trials":1496,"activeCount":61},[],{"trials":1498,"activeCount":61},[1499],{"nctId":1500,"briefTitle":1501,"status":113,"phases":1502,"primaryCompletion":1503,"completion":1504,"start":1069,"enrollment":810,"conditions":1505,"interventions":1506},"NCT01441102","Dextromethorphan for Diabetic Macular Edema",[50,51],"2014-06","2015-12",[154],[1491],{"trials":1508,"activeCount":61},[],{"trials":1510,"activeCount":61},[],{"trials":1512,"activeCount":61},[],{"intervention":1514,"totalTrials":57,"cells":1515},"NP-016 Vaccine Immune Globulin",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1531,"PHASE4":1533,"NA":1535},{"trials":1517,"activeCount":61},[],{"trials":1519,"activeCount":61},[],{"trials":1521,"activeCount":61},[1522],{"nctId":1523,"briefTitle":1524,"status":113,"phases":1525,"completion":127,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1530},"NCT00081835","Evaluation and Treatment of Eye Complications of Vaccinia Vaccination",[51],"2004-04-19",400,[1529],"Vaccinia",[1514],{"trials":1532,"activeCount":61},[],{"trials":1534,"activeCount":61},[],{"trials":1536,"activeCount":61},[],{"intervention":1538,"totalTrials":57,"cells":1539},"Avastin",{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1541,"activeCount":61},[],{"trials":1543,"activeCount":61},[],{"trials":1545,"activeCount":61},[1546],{"nctId":1547,"briefTitle":1548,"status":260,"phases":1549,"completion":1550,"start":1551,"enrollment":117,"conditions":1552,"interventions":1553},"NCT00464347","TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration",[51],"2007-09","2007-01",[27],[1538,1554],"Preservative-Free Triamcinolone Acetonide",{"trials":1556,"activeCount":61},[],{"trials":1558,"activeCount":61},[],{"trials":1560,"activeCount":61},[],{"intervention":1554,"totalTrials":57,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":61},[],{"trials":1566,"activeCount":61},[],{"trials":1568,"activeCount":61},[1569],{"nctId":1547,"briefTitle":1548,"status":260,"phases":1570,"completion":1550,"start":1551,"enrollment":117,"conditions":1571,"interventions":1572},[51],[27],[1538,1554],{"trials":1574,"activeCount":61},[],{"trials":1576,"activeCount":61},[],{"trials":1578,"activeCount":61},[],{"intervention":1580,"totalTrials":57,"cells":1581},"Sunitinib Malate",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1583,"activeCount":61},[],{"trials":1585,"activeCount":61},[],{"trials":1587,"activeCount":61},[1588],{"nctId":1589,"briefTitle":1590,"status":260,"phases":1591,"primaryCompletion":1321,"completion":1321,"start":855,"enrollment":11,"conditions":1592,"interventions":1593},"NCT00673816","Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome",[50,51],[930],[1580],{"trials":1595,"activeCount":61},[],{"trials":1597,"activeCount":61},[],{"trials":1599,"activeCount":61},[],{"intervention":1601,"totalTrials":57,"cells":1602},"Intravenous Daclizumab",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1604,"activeCount":61},[],{"trials":1606,"activeCount":61},[],{"trials":1608,"activeCount":61},[1609],{"nctId":1610,"briefTitle":1611,"status":113,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":33,"conditions":1615,"interventions":1617},"NCT00304954","Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration",[51],"2010-01","2006-02",[27,1616],"Choroidal Neovascularization",[1601,1618,1619],"Intravenous Infliximab","Oral Rapamycin",{"trials":1621,"activeCount":61},[],{"trials":1623,"activeCount":61},[],{"trials":1625,"activeCount":61},[],{"intervention":1618,"totalTrials":57,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1629,"activeCount":61},[],{"trials":1631,"activeCount":61},[],{"trials":1633,"activeCount":61},[1634],{"nctId":1610,"briefTitle":1611,"status":113,"phases":1635,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":33,"conditions":1636,"interventions":1637},[51],[27,1616],[1601,1618,1619],{"trials":1639,"activeCount":61},[],{"trials":1641,"activeCount":61},[],{"trials":1643,"activeCount":61},[],{"intervention":1619,"totalTrials":57,"cells":1645},{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1647,"activeCount":61},[],{"trials":1649,"activeCount":61},[],{"trials":1651,"activeCount":61},[1652],{"nctId":1610,"briefTitle":1611,"status":113,"phases":1653,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":33,"conditions":1654,"interventions":1655},[51],[27,1616],[1601,1618,1619],{"trials":1657,"activeCount":61},[],{"trials":1659,"activeCount":61},[],{"trials":1661,"activeCount":61},[],{"intervention":1663,"totalTrials":57,"cells":1664},"Acetazolamide",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1666,"activeCount":61},[],{"trials":1668,"activeCount":61},[],{"trials":1670,"activeCount":61},[1671],{"nctId":1672,"briefTitle":1673,"status":113,"phases":1674,"completion":1675,"start":1676,"conditions":1677,"interventions":1678},"NCT00000115","Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema",[51],"1994-06","1990-12",[165],[1663],{"trials":1680,"activeCount":61},[],{"trials":1682,"activeCount":61},[],{"trials":1684,"activeCount":61},[],{"intervention":1686,"totalTrials":57,"cells":1687},"Cyclosporin A",{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1689,"activeCount":61},[],{"trials":1691,"activeCount":61},[],{"trials":1693,"activeCount":61},[1694],{"nctId":1695,"briefTitle":1696,"status":113,"phases":1697,"completion":1698,"start":1699,"enrollment":174,"conditions":1700,"interventions":1703},"NCT00001731","Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops",[51],"2000-10","1997-11",[1701,1702],"Keratoconjunctivitis Sicca","Sjogren's Syndrome",[1686],{"trials":1705,"activeCount":61},[],{"trials":1707,"activeCount":61},[],{"trials":1709,"activeCount":61},[],{"intervention":1711,"totalTrials":57,"cells":1712},"Leflunomide",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1714,"activeCount":61},[],{"trials":1716,"activeCount":61},[],{"trials":1718,"activeCount":61},[1719],{"nctId":1720,"briefTitle":1721,"status":113,"phases":1722,"completion":214,"start":1723,"enrollment":129,"conditions":1724,"interventions":1725},"NCT00001863","Leflunomide to Treat Uveitis",[51],"1999-03",[15],[1711],{"trials":1727,"activeCount":61},[],{"trials":1729,"activeCount":61},[],{"trials":1731,"activeCount":61},[],{"intervention":1733,"totalTrials":57,"cells":1734},"Infliximab",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1746,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1736,"activeCount":61},[],{"trials":1738,"activeCount":61},[1739],{"nctId":1740,"briefTitle":1741,"status":113,"phases":1742,"completion":820,"start":1743,"enrollment":152,"conditions":1744,"interventions":1745},"NCT00075075","Infliximab to Treat Non-Infectious Scleritis",[50],"2003-12-23",[1002],[1733],{"trials":1747,"activeCount":61},[],{"trials":1749,"activeCount":61},[],{"trials":1751,"activeCount":61},[],{"trials":1753,"activeCount":61},[],{"intervention":1755,"totalTrials":57,"cells":1756},"Palomid 529",{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1758,"activeCount":61},[],{"trials":1760,"activeCount":61},[1761],{"nctId":1762,"briefTitle":1763,"status":113,"phases":1764,"primaryCompletion":1765,"completion":1765,"start":1766,"enrollment":152,"conditions":1767,"interventions":1768},"NCT01271270","Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration",[50],"2012-09-20","2010-12-20",[27],[1755],{"trials":1770,"activeCount":61},[],{"trials":1772,"activeCount":61},[],{"trials":1774,"activeCount":61},[],{"trials":1776,"activeCount":61},[],{"intervention":1778,"totalTrials":57,"cells":1779},"Cyclosporin A Implant",{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1792,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1781,"activeCount":61},[],{"trials":1783,"activeCount":61},[1784],{"nctId":1785,"briefTitle":1786,"status":113,"phases":1787,"completion":1788,"start":1209,"enrollment":1393,"conditions":1789,"interventions":1791},"NCT00001737","Cyclosporin Implant to Treat Uveitis",[50],"2004-03",[1346,1790,15],"Inflammation",[1778],{"trials":1793,"activeCount":61},[],{"trials":1795,"activeCount":61},[],{"trials":1797,"activeCount":61},[],{"trials":1799,"activeCount":61},[],{"intervention":1801,"totalTrials":57,"cells":1802},"Subconjunctival Cyclosporine Implant",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1804,"activeCount":61},[],{"trials":1806,"activeCount":61},[1807],{"nctId":1808,"briefTitle":1809,"status":113,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":247,"conditions":1813,"interventions":1815},"NCT00102583","Cyclosporine Implant for Ocular Graft-Versus-Host Disease",[50],"2011-03-15","2004-10-14",[1814],"Graft Vs Host Disease",[1801],{"trials":1817,"activeCount":61},[],{"trials":1819,"activeCount":61},[],{"trials":1821,"activeCount":61},[],{"trials":1823,"activeCount":61},[],{"intervention":1825,"totalTrials":57,"cells":1826},"Rituximab",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1840,"PHASE3":1842,"PHASE4":1844,"NA":1846},{"trials":1828,"activeCount":61},[],{"trials":1830,"activeCount":61},[1831],{"nctId":1832,"briefTitle":1833,"status":113,"phases":1834,"completion":1835,"start":1836,"enrollment":152,"conditions":1837,"interventions":1839},"NCT01086631","Rituximab for Autoimmune Retinopathy",[50],"2014-07-08","2010-01-22",[1838],"Autoimmune Disease",[1825],{"trials":1841,"activeCount":61},[],{"trials":1843,"activeCount":61},[],{"trials":1845,"activeCount":61},[],{"trials":1847,"activeCount":61},[],{"intervention":1849,"totalTrials":57,"cells":1850},"Interferon Gamma 1-b",{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1863,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1852,"activeCount":61},[],{"trials":1854,"activeCount":61},[1855],{"nctId":1856,"briefTitle":1857,"status":113,"phases":1858,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":152,"conditions":1861,"interventions":1862},"NCT00943982","The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma",[50],"2010-06-24","2009-07-17",[15],[1849],{"trials":1864,"activeCount":61},[],{"trials":1866,"activeCount":61},[],{"trials":1868,"activeCount":61},[],{"trials":1870,"activeCount":61},[],{"intervention":1872,"totalTrials":57,"cells":1873},"valacyclovir hydrochloride",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1886,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1875,"activeCount":61},[],{"trials":1877,"activeCount":61},[1878],{"nctId":1879,"briefTitle":1880,"status":225,"phases":1881,"primaryCompletion":980,"completion":980,"start":1882,"enrollment":205,"conditions":1883,"interventions":1884},"NCT00587496","30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers",[50],"2006-04",[348],[1872,1885],"valacyclovir plus aspirin",{"trials":1887,"activeCount":61},[],{"trials":1889,"activeCount":61},[],{"trials":1891,"activeCount":61},[],{"trials":1893,"activeCount":61},[],{"intervention":1885,"totalTrials":57,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1897,"activeCount":61},[],{"trials":1899,"activeCount":61},[1900],{"nctId":1879,"briefTitle":1880,"status":225,"phases":1901,"primaryCompletion":980,"completion":980,"start":1882,"enrollment":205,"conditions":1902,"interventions":1903},[50],[348],[1872,1885],{"trials":1905,"activeCount":61},[],{"trials":1907,"activeCount":61},[],{"trials":1909,"activeCount":61},[],{"trials":1911,"activeCount":61},[],{"intervention":1913,"totalTrials":57,"cells":1914},"Corticosteroid",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1916,"activeCount":61},[],{"trials":1918,"activeCount":61},[1919],{"nctId":1920,"briefTitle":1921,"status":113,"phases":1922,"completion":1923,"start":1924,"enrollment":1925,"conditions":1926,"interventions":1927},"NCT00001615","Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration",[50],"2000-05","1997-07",180,[1616,18],[1913],{"trials":1929,"activeCount":61},[],{"trials":1931,"activeCount":61},[],{"trials":1933,"activeCount":61},[],{"trials":1935,"activeCount":61},[],{"intervention":1937,"totalTrials":57,"cells":1938},"Ciliary Neurotrophic Factor Implant NT-501",{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1940,"activeCount":61},[],{"trials":1942,"activeCount":61},[1943],{"nctId":1944,"briefTitle":1945,"status":113,"phases":1946,"completion":1947,"start":1948,"enrollment":1393,"conditions":1949,"interventions":1950},"NCT00063765","Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye",[50],"2006-03","2003-06",[32],[1937],{"trials":1952,"activeCount":61},[],{"trials":1954,"activeCount":61},[],{"trials":1956,"activeCount":61},[],{"trials":1958,"activeCount":61},[],{"intervention":1960,"totalTrials":57,"cells":1961},"OGT918",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1963,"activeCount":61},[],{"trials":1965,"activeCount":61},[1966],{"nctId":1967,"briefTitle":1968,"status":113,"phases":1969,"completion":127,"start":1970,"enrollment":174,"conditions":1971,"interventions":1973},"NCT00316498","Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease",[50],"2002-10-17",[1972],"Niemann Pick Diseases",[1960],{"trials":1975,"activeCount":61},[],{"trials":1977,"activeCount":61},[],{"trials":1979,"activeCount":61},[],{"trials":1981,"activeCount":61},[],{"intervention":1983,"totalTrials":57,"cells":1984},"Docosahexaenoic Acid (DHA) Dietary Supplement",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1986,"activeCount":61},[],{"trials":1988,"activeCount":61},[1989],{"nctId":1990,"briefTitle":1991,"status":113,"phases":1992,"completion":1993,"start":1994,"enrollment":1995,"conditions":1996,"interventions":1997},"NCT00060749","Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy",[50],"2007-12-10","2003-05-05",22,[18],[1983],{"trials":1999,"activeCount":61},[],{"trials":2001,"activeCount":61},[],{"trials":2003,"activeCount":61},[],{"trials":2005,"activeCount":61},[],{"intervention":2007,"totalTrials":57,"cells":2008},"Fluocinolone",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2010,"activeCount":61},[],{"trials":2012,"activeCount":61},[2013],{"nctId":2014,"briefTitle":2015,"status":113,"phases":2016,"completion":2017,"start":2018,"enrollment":129,"conditions":2019,"interventions":2020},"NCT00008515","Fluocinolone Implant to Treat Macular Degeneration",[50],"2001-12","2001-01",[1616,18],[2007],{"trials":2022,"activeCount":61},[],{"trials":2024,"activeCount":61},[],{"trials":2026,"activeCount":61},[],{"trials":2028,"activeCount":61},[],{"intervention":2030,"totalTrials":57,"cells":2031},"Chicken type II collagen",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2042,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2033,"activeCount":61},[],{"trials":2035,"activeCount":61},[2036],{"nctId":2037,"briefTitle":2038,"status":113,"phases":2039,"completion":1923,"start":1924,"enrollment":33,"conditions":2040,"interventions":2041},"NCT00001614","The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis",[50],[740,15],[2030],{"trials":2043,"activeCount":61},[],{"trials":2045,"activeCount":61},[],{"trials":2047,"activeCount":61},[],{"trials":2049,"activeCount":61},[],{"intervention":2051,"totalTrials":57,"cells":2052},"EYE001",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2064,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2054,"activeCount":61},[],{"trials":2056,"activeCount":61},[2057],{"nctId":2058,"briefTitle":2059,"status":113,"phases":2060,"completion":161,"start":1278,"enrollment":152,"conditions":2061,"interventions":2063},"NCT00056199","EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome",[50],[2062],"Hippel-Lindau Disease",[2051],{"trials":2065,"activeCount":61},[],{"trials":2067,"activeCount":61},[],{"trials":2069,"activeCount":61},[],{"trials":2071,"activeCount":61},[],{"intervention":2073,"totalTrials":57,"cells":2074},"Efalizumab",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2076,"activeCount":61},[],{"trials":2078,"activeCount":61},[2079],{"nctId":2080,"briefTitle":2081,"status":113,"phases":2082,"primaryCompletion":1188,"completion":1188,"start":2083,"enrollment":106,"conditions":2084,"interventions":2085},"NCT00280826","Efalizumab to Treat Uveitis",[50],"2006-01",[15,166],[2073],{"trials":2087,"activeCount":61},[],{"trials":2089,"activeCount":61},[],{"trials":2091,"activeCount":61},[],{"trials":2093,"activeCount":61},[],{"intervention":2095,"totalTrials":11,"cells":2096},"Vitamin A palmitate",{"EARLY_PHASE1":2097,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2098,"activeCount":61},[2099,2108],{"nctId":2100,"briefTitle":2101,"status":113,"phases":2102,"primaryCompletion":2103,"completion":2103,"start":2104,"enrollment":1247,"conditions":2105,"interventions":2107},"NCT03478865","Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation",[49],"2023-06-16","2018-04-20",[2106],"AMD",[2095],{"nctId":2109,"briefTitle":2110,"status":113,"phases":2111,"primaryCompletion":2112,"completion":2112,"start":2113,"enrollment":36,"conditions":2114,"interventions":2116},"NCT03478878","Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation",[49],"2022-06-17","2018-05-14",[2115,27],"Reticular Pseudodrusen (RPD)",[2117],"Vitamin A Palmitate",{"trials":2119,"activeCount":61},[],{"trials":2121,"activeCount":61},[],{"trials":2123,"activeCount":61},[],{"trials":2125,"activeCount":61},[],{"trials":2127,"activeCount":61},[],{"intervention":2129,"totalTrials":11,"cells":2130},"Methylprednisolone",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2148,"NA":2150},{"trials":2132,"activeCount":61},[],{"trials":2134,"activeCount":61},[],{"trials":2136,"activeCount":61},[],{"trials":2138,"activeCount":61},[2139],{"nctId":2140,"briefTitle":2141,"status":225,"phases":2142,"start":2143,"conditions":2144,"interventions":2146},"NCT00000146","Optic Neuritis Treatment Trial (ONTT)",[52],"1988-07",[2145,633],"Multiple Sclerosis",[2129,2147],"Prednisone",{"trials":2149,"activeCount":61},[],{"trials":2151,"activeCount":61},[2152],{"nctId":2153,"briefTitle":2154,"status":225,"phases":2155,"start":2143,"conditions":2156,"interventions":2157},"NCT00000147","Longitudinal Optic Neuritis Study (LONS)",[54],[2145,633],[2129,2147],{"intervention":2147,"totalTrials":11,"cells":2159},{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2164,"PHASE3":2166,"PHASE4":2172,"NA":2174},{"trials":2161,"activeCount":61},[],{"trials":2163,"activeCount":61},[],{"trials":2165,"activeCount":61},[],{"trials":2167,"activeCount":61},[2168],{"nctId":2140,"briefTitle":2141,"status":225,"phases":2169,"start":2143,"conditions":2170,"interventions":2171},[52],[2145,633],[2129,2147],{"trials":2173,"activeCount":61},[],{"trials":2175,"activeCount":61},[2176],{"nctId":2153,"briefTitle":2154,"status":225,"phases":2177,"start":2143,"conditions":2178,"interventions":2179},[54],[2145,633],[2129,2147]]